|
|
|
|
Chronic Myeloproliferative Disorders
Genzyme launches test to monitor Gleevec resistance Feb 13, 2006
News-Medical.net, Genzyme has also made available a new assay that detects a mutation in the Janus kinase 2 (JAK2) gene common in chronic myeloproliferative disorders (MPDs). ...
Hydrea Trumps Agrylin as First Line Therapy for High Risk ... -- Jul 6, 2005
...groups. Essential thrombocythemia, one of the chronic myeloproliferative disorders, is a clonal hematologic stem-cell disorder. ... / MedPage Today,
Books, Journals, New Media Received -- Mar 15, 2005
Molecular Basis of Chronic Myeloproliferative Disorders edited by Petro E. Petrides and Heike L. Pahl (meeting, Frauenchiemsee, Bavaria), 218 pp, with illus ... / Journal of American Medical Association (subscription),
Books, Journals, New Media Received Mar 15, 2005
Molecular Basis of Chronic Myeloproliferative Disorders edited by Petro E. Petrides and Heike L. Pahl (meeting, Frauenchiemsee, Bavaria), 218 pp, with illus ... Journal of American Medical Association (subscription)
The myeloproliferative diseases are a group of diseases of the bone marrow where excess cells are produced. The delineation from leukemia is artificial, although the myeloproliferative diseases on the whole have a much better prognosis than the leukemias. The concept was first proposed in 1951 by the eminent hematologist William Dameshek.
The myeloproliferative diseases are:- Chronic myelogenous leukemia (CML)
- Polycythemia vera (PCV)
- Essential thrombocytosis (ET)
- Myelofibrosis (increased connective tissue with decreased room for production of normal blood cells).
All MPDs arise from precursors of the "myeloid" lineage in the bone marrow. The lymphoid lineage may produce similar diseases, the lymphoproliferative disorders (acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma).
|
|
|
